Inferra AI / Company / SRPT
Sarepta Therapeutics, Inc.
SRPT · Health Care
Last earnings Aug 5, 2026
Key results
Operating incomequarter
$358.4 million
operating income of $358.4 million and $397.7 million for the first quarter 2026, respectively –
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Revenuequarter
$253.0 million
The decrease is partially offset by an increase of $253.0 million in collaboration revenues related to the $365.0 million of collaboration revenue recognized related to F.
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
's (“Roche”) declined option for certain program rights and the milestone recognized under the Roche collaboration agreement for the first commercial dosing of ELEVIDYS in Japan during the first quarter of 2026, as compared to $112.0 million of collaboration revenue in 2025 related to Roche’s expiration of an option to acquire a certain program.
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
AI analysis
Q1 2026 · reported May 6, 2026
Based on: Earnings release + parent 8-K — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · May 6, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q1 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Operating income | $358.4 million | — | — |
| Revenue | $253.0 million | — | — |
Guidance · company-stated
Direction: Reiterated
“• Reiterate FY 2026 guidance: Total net product revenues of $1.2 - $1.4 billion, and combined non-GAAP R&D and SG&A expenses of $800.0 - $900.0 million.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Interest, depreciation and amortization - Interest expense/income, net amounts can vary substantially from period to period due to changes in cash and debt balances and interest rates driven by market conditions outside of our operations.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +453.4% computed from stated figures
Event summary
Finally, we remain in a position of financial strength, with positive earnings, and continued cash flow generation that enables us to fully fund our pipeline
Based on: Earnings release + parent 8-K — transcript not held
Guidance & outlook
Direction: Reiterated
Revenue: “• Reiterate FY 2026 guidance: Total net product revenues of $1.2 - $1.4 billion, and combined non-GAAP R&D and SG&A expenses of $800.0 - $900.0 million.”
Revenue — Reiterated (“Reiterate”)
“• Reiterate FY 2026 guidance: Total net product revenues of $1.2 - $1.4 billion, and combined non-GAAP R&D and SG&A expenses of $800.0 - $900.0 million.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Interest, depreciation and amortization - Interest expense/income, net amounts can vary substantially from period to period due to changes in cash and debt balances and interest rates driven by market conditions outside of our operations.
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Strategy & priorities
We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta’s next era.
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
(“Arrowhead”) executed during the three months ended March 31, 2025, as well as a decrease in manufacturing and clinical expenses primarily due to our decision to reprioritize our pipeline and developmental priorities announced in July 2025.
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
The change primarily reflects a decrease in our loss on strategic investments related to our investment in Arrowhead, which was sold in August 2025, partially offset by an increase in interest expense due to the 2030 Notes carrying a higher interest rate than our 2027 Notes during the three months ended March 31, 2026.
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
These other items include the loss (gain) on strategic investments and may include other items that fit the above characteristics in the future.
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
We exclude from our non-GAAP results: a) The loss (gain) on strategic investments as the results of such gains and losses are not representative of our normal business operations, which would make it difficult to compare our results to peer companies that also provide non-GAAP disclosures.
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Risks & headwinds
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control.
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Actual results could materially differ from those stated or implied by these forward-looking 12 statements as a result of such risks and uncertainties.
SEC original ↗Sarepta Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
34 documents- Q2 2026
- 8-KSRPT
Sep 23, 2026
- 10-QSRPT
- 8-KSRPT
- 8-KSRPT
Jul 27, 2026
- Q1 2026
- 8-KSRPT
- 10-QSRPT
- 8-KSRPT
- Q4 2025
- 10-KSRPT
- 8-KSRPT
Feb 25, 2026
- 8-KSRPT
Feb 25, 2026
- 8-KSRPT
Jan 12, 2026
- EX-99SRPT
- Q3 2025
- 8-KSRPT
Dec 19, 2025
- 8-KSRPT
Dec 11, 2025
- EX-99SRPT
- 8-KSRPT
- 10-QSRPT
- 8-KSRPT
- Q2 2025
- 8-KSRPT
Aug 29, 2025
- 8-KSRPT
Aug 21, 2025
- 8-KSRPT
Aug 13, 2025
- 10-QSRPT
- 8-KSRPT
Jul 21, 2025
- 8-KSRPT
Jul 16, 2025
- EX-99SRPT
- Q1 2025
- 8-KSRPT
- 10-QSRPT
- Q4 2024
- 10-KSRPT
Feb 28, 2025
- 8-KSRPT
Feb 26, 2025
- 8-KSRPT
Feb 14, 2025
- 8-KSRPT
Jan 13, 2025
- EX-99SRPT
- Q3 2024
- 8-KSRPT
Nov 26, 2024
- 10-QSRPT
Earnings releases
6 documentsPresentations
0 documentsNo presentations for Sarepta Therapeutics, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Sarepta Therapeutics, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.